DataMeds AI, Inc. (WGRX) Form 8-K — Oct 26, 2026
DataMEDS AI (NASDAQ: MEDS) entered a non-binding Second Amended and Restated LOI dated October 19, 2026 with EOS Technology Holdings, Scilex (SCLX), Datavault AI (DVLT), HealthBridge Advisors, Tollo Health and REBOOT Health AI, superseding all prior LOIs and term sheets for the combined acquisition/licensing of the QLPM IP portfolio, expanded Datavault AI Health license, and a controlling interest in Health Lives Here. In exchange for stock consideration, EOS, Scilex, Datavault, Fortitude, HBA/THI and REBOOT would own approximately 89.5% of the company post-closing on a fully diluted basis, leaving existing public stockholders with roughly 10.5%.
Key figures
- Tam 2025 usd
- 9.6 billion
- Tam 2035 usd
- 93.4 billion
- Lockup months
- 6
- Expected close
- Q4 2026
- Pharmacy network
- 6500
- Eos royalty percent
- 5
- Exclusivity through
- 2026-11-30
- Eos post close percent
- 14.9
- Reboot royalty percent
- 6
- Scilex royalty percent
- 5
- S3 filing deadline days
- 45
- Immediate capital min usd
- 2000000
- Insider ownership percent
- 89.5
- Reboot post close percent
- 9.9
- Scilex post close percent
- 14.9
- Hba thi post close percent
- 24.9
- Liability threshold max usd
- 2000000
- Datavault post close percent
- 19.9
- Fortitude post close percent
- 5
- Legal fee reimbursement cap usd
- 250000
- Post closing public float percent
- 10.5
- Dawson james investors prior investment usd
- 6500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.